Article
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.
Antimicrobial agents and chemotherapy - 21 Feb 2020
Arendrup Maiken Cavling, Jørgensen Karin Meinike, Hare Rasmus Krøger, Chowdhary Anuradha
Abstract excerpt
Ibrexafungerp (SCY-078) is a novel first-in-class antifungal agent targeting glucan synthase. Candida auris is an emerging multidrug-resistant species that has caused outbreaks on five continents. We investigated the in vitro activity of ibrexafungerp against C. auris by applying EUCAST E.Def 7.3.1 methodology. C. albicans and C. glabrata, as well as anidulafungin, micafungin, amphotericin B, fluconazole,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.